The intergroup rhabdomyosarcoma study‐I. A final report

  title={The intergroup rhabdomyosarcoma study‐I. A final report},
  author={Harold M. Maurer and William M. Crist and Walter Lawrence and Abdelsalam H. Ragab and Richard Beverly Raney and Bruce L. Webber and Moody D. Wharam and Teresa J. Vietti and Mohan S. Beltangady and Edmund A. Gehan and Denman Hammond and Daniel M. Hays and Ruth M. Heyn and William A. Newton and Jorge A. Ortega and Frederick B. Ruymann and Edward H. Soule and Melvin Tefft},
The results of treatment of 686, previously untreated patients younger than 21 years with rhabdomyosarcoma or undifferentiated sarcoma, who were entered on Intergroup Rhabdomyosarcoma Study‐I (IRS‐I) were analyzed after a minimum potential follow‐up time of 7 years. Patients in Clinical Group I (localized disease, completely resected) were randomized to receive either vincristine, dactinomycin, and cyclophosphamide (VAC) or VAC + radiation. At 5 years, approximately 80% of patients given either… 
The Third Intergroup Rhabdomyosarcoma Study.
  • W. Crist, E. Gehan, R. Heyn
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1995
Intensification of therapy for most patients in IRS-III, using a risk-based study design, significantly improved treatment outcome overall and was also possible to decrease therapy for selected patient subsets without compromising survival.
Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease.
VAC and VAI or VIE with surgery (with or without RT), are equally effective for patients with local or regional rhabdomyosarcoma and are more effective for embryonal tumors than therapies used previously.
Group II rhabdomyosarcoma and rhabdomyosarcomalike tumors: is radiotherapy necessary?
No subgroup could be defined for which the omission of radiotherapy produced outcome equivalent to that of patients who were irradiated, and local control and EFS in group II patients are improved with radiotherapy.
Treatment of Adult Rhabdomyosarcoma
This study examines short-term outcomes using doxorubicin, ifosfamide, and vincristine for adult rhabdomyosarcoma and yields 55% overall and 64% disease-free survival at 2 years.
Improved outcome for patients with middle ear rhabdomyosarcoma: a children's oncology group study.
  • D. Hawkins, J. Anderson, W. Crist
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2001
Patients with ME RMS generally present with small, unresectable, invasive tumors at a site traditionally considered prognostically unfavorable, Nevertheless, such patients have benefited markedly from improvements in multimodal, risk-based therapy during the course of IRS I through IV, and with contemporary therapy, most are cured.
Paratesticular rhabdomyosarcoma: Importance of initial therapy.
Long-Term Survival Results of Pediatric Rhabdomyosarcoma Patients: A Single-Center Experience From Turkey
In children with rhabdomyosarcoma, survival rates can be improved owing to factors such as advancement in diagnostic and therapeutic techniques, improved supportive care, and a multidisciplinary approach.
Adult rhabdomyosarcoma survival improved with treatment on multimodality protocols.
Current status of treatment for pediatric rhabdomyosarcoma in the USA and Japan
  • H. Hosoi
  • Medicine
    Pediatrics international : official journal of the Japan Pediatric Society
  • 2016
The current status of treatment for children with rhabdomyosarcoma is reviewed, according to the four risk groups, with overall survival approximately 30% and has not improved over the last 25 years.


The intergroup rhabdomyosarcoma study. A preliminary report
There is no indication as yet that one treatment regimen is superior to the other in the Intergroup Rhabdomyosarcoma Study, and over 85% of patients on either treatment have no evidence of disease and 90% are still alive.
Prognosis in childhood rhabdomyosarcoma
Survival data on 78 children with rhabdomyosarcoma indicated that age, histology, primary site, extent of disease, and treatment each had a significant influence on prognosis. The best survival
Extraskeletal neoplasm resembling Ewing's sarcoma
The pathologic features and the behavior of 39 small, round, or oval cell sarcomas occurring in the soft tissues and considered histologically indistinguishable from Ewing's sarcoma of bone are reviewed.
Statistical aspects of the analysis of data from retrospective studies of disease.
The role and limitations of retrospective investigations of factors possibly associated with the occurrence of a disease are discussed and their relationship to forward-type studies emphasized.
Nonparametric Estimation from Incomplete Observations
Abstract In lifetesting, medical follow-up, and other fields the observation of the time of occurrence of the event of interest (called a death) may be prevented for some of the items of the sample
Some comparisons are made for five cases of varying degrees of censoring and tying between probabilities from the exact test and those from the proposed test and these suggest the test is appropriate under certain conditions when the sample size is five in each group.